Arsenic trioxide (As2O3) induced selective apoptosis in acute promyelocytic leukemia (APL) cells involves a hydrogen peroxide (H2O2) dependent pathway.

被引：0
|
作者：
Jing, Y
Dai, J
Cohen, M
Weinberg, RS
Chalmers-Redmen, RME
Tatton, WG
Waxman, S
机构：
[1] CUNY Mt Sinai Sch Med, Rochelle Belfer Chemotherapy Fdn Lab, Div Neoplast Dis, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Dept Med, Div Hematol, New York, NY 10029 USA
[3] CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2453
引用
收藏
页码：595A / 595A
页数：1
相关论文
共 50 条
  • [1] Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) .1. As2O3 exerts dose-dependent dual effects on APL cells
    Chen, GQ
    Shi, XG
    Tang, W
    Xiong, SM
    Zhu, J
    Cai, X
    Han, ZG
    Ni, JH
    Shi, GY
    Jia, PM
    Liu, MM
    He, KL
    Niu, C
    Ma, J
    Zhang, P
    Zhang, TD
    Paul, P
    Naoe, T
    Kitamura, K
    Miller, W
    Waxman, S
    Wang, ZY
    deThe, H
    Chen, SJ
    Chen, Z
    BLOOD, 1997, 89 (09) : 3345 - 3353
  • [2] The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia
    Zhang, P
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 1999, 13 (04): : 195 - 200
  • [3] The in vitro study of apoptosis induced with arsenic trioxide (As2O3) and other Chinese medications in acute promyelocytic leukemia (APL) and chronic myelocytic leukemia (CML).
    Liu, JW
    Jun, M
    Ying, W
    BLOOD, 1998, 92 (10) : 193B - 193B
  • [4] Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (As2O3,)
    Zhang, T
    Westervelt, P
    Hess, JL
    LABORATORY INVESTIGATION, 1999, 79 (01) : 150A - 150A
  • [5] Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL).: The MD Anderson experience.
    Lazo, G
    Cortes, J
    O'Brien, S
    Estey, E
    Thomas, D
    Kantarjian, H
    BLOOD, 2001, 98 (11) : 595A - 596A
  • [6] Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line
    Noh, Eui-Kyu
    Kim, Hawk
    Park, Min Jae
    Baek, Jin Ho
    Park, Jae-Hoo
    Cha, Seung Joo
    Won, Jong-Ho
    Min, Young Joo
    LEUKEMIA RESEARCH, 2010, 34 (11) : 1501 - 1505
  • [7] Western study of arsenic trioxide (As2O3) in patients with relapsed and/or refractory acute promyelocytic leukemia
    Soignet, SL
    Maslak, P
    Chen, YW
    Calleja, E
    Pandolfi, PP
    Scheinberg, DA
    Warrell, RP
    ANNALS OF ONCOLOGY, 1998, 9 : 176 - 176
  • [8] Clinical observations on arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
    Ma, J
    Liu, JW
    Chen, LY
    Liang, H
    Zhang, Y
    BLOOD, 1998, 92 (10) : 483A - 483A
  • [9] P-glycoprotein (P-gp) is induced by arsenic trioxide (As2O3) therapy, but is not the main mechanism of As2O3 resistance in acute promyelocytic leukemia (APL) cells:: Analysis of P-gp and intracellular concentration of As2O3.
    Takeshita, A
    Shinjo, K
    Naito, K
    Horie, T
    Maekawa, M
    Kitamura, K
    Ohnishi, K
    Naoe, T
    Ohno, R
    BLOOD, 2001, 98 (11) : 596A - 597A
  • [10] Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3)
    Zhang, T
    Westervelt, P
    Hess, JL
    MODERN PATHOLOGY, 2000, 13 (09) : 954 - 961
12345